SPANX-A-E Inhibitors
SPANX-A-E Inhibitors refers to a group of chemical compounds designed to selectively target and inhibit specific members of the SPANX-A-E gene family. These inhibitors are primarily developed for research purposes and have shown promise in elucidating the biological functions of SPANX genes. SPANX (Sperm Protein Associated with the Nucleus on the X chromosome) genes are a family of cancer-testis antigens located on the X chromosome. They are typically expressed in the testes but can also be found in various cancer types, making them potential targets for cancer research.
The mechanism of action of SPANX-A-E inhibitors involves the interference with the expression or activity of SPANX genes. These inhibitors often act at the molecular level, either by blocking the transcription of SPANX genes or by disrupting the functions of SPANX proteins. This interference can help researchers gain insights into the roles of SPANX genes in normal physiological processes and their potential involvement in cancer development. By inhibiting SPANX gene expression or function, these inhibitors contribute to our understanding of the molecular mechanisms underlying cancer progression and may offer valuable information for future research into cancer biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used for B-cell malignancies. It irreversibly binds to BTK, blcoking B-cell activation and proliferation. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, inhibiting the abnormal signaling in chronic myeloid leukemia (CML) and some other cancers. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib is an EGFR (epidermal growth factor receptor) inhibitor that selectively targets mutant EGFR proteins in non-small cell lung cancer (NSCLC). It inhibits tumor growth. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple kinases involved in tumor angiogenesis and cell proliferation, including Raf kinases and VEGFR, to slow the growth of certain cancers. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor used in multiple myeloma therapy. It disrupts protein degradation in cancer cells, leading to apoptosis (cell death). | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib targets multiple receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis. It is used for advanced renal cell carcinoma (RCC) and other cancers. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide is an immunomodulatory drug used in multiple myeloma and myelodysplastic syndromes. It affects the immune system and inhibits tumor cell growth through various mechanisms. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor used in myelofibrosis and polycythemia vera. It inhibits JAK signaling pathways, reducing abnormal cell growth. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
ABT-199, also called Venetoclax, is a B-cell lymphoma-2 (BCL-2) inhibitor used in chronic lymphocytic leukemia (CLL). It promotes apoptosis by targeting BCL-2, an anti-apoptotic protein in cancer cells. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor used for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It targets BCR-ABL. | ||||||